cyrilzakka/clinical-trials huggingface dataset:
To Evaluate the Role of Lung Ultrasonography for Detection of Atlelectasis in Robot Assisted Laproscopic Pelvic Sugeries

Pre op ultrasound with chest auscultation and arterial blood gas, after extubation ultrasound with chest auscultation and blood gas, 12hrs chest auscultation with ultasaound, 24 hrs chest auscultation and ultrasound to see atelectasis

Pre op ultrasound with chest auscultation and arterial blood gas, after extubation ultrasound with chest auscultation and blood gas, 12hrs chest auscultation with ultasaound, 24 hrs chest auscultation and ultrasound to see atelectasis inclusion criteria: age 18 to 70 yrs age ASA I and II robot assisted pelvic surgeries in steep trendelenburg position

exclusion criteria: cardiac disese severe obstructive and restrictive disease upper airways infection ASAIII and IV

Eligibility Criteria:
Inclusion Criteria:

* ASA Iand II age 18-70 yrs robot assisted pelvis surgeries

Exclusion Criteria:

* ASA II and IV cardiac and lung disease
Diaphragmatic Dysfunction After Ultrasound-guided Supraclavicular Block With Single or Double Injection Technique

The investigators plan to determine the incidence of hemi-diaphragmatic paresis (HDP) with two commonly used techniques of supraclavicular nerve block, the single and double injection techniques.

It is our hypothesis that a double injection peripheral nerve block technique will increase the risk of HDP when compared to a single injection technique.

The investigators will perform a prospective, blinded, randomized controlled trial to assess the two methods of supraclavicular block (single and double injection), and the resultant incidence of temporary diaphragm dysfunction, or hemi-diaphragmatic paresis (HDP) will be measured with ultrasound. Patients having forearm or hand surgery will be asked by the attending anesthesiologist if they will agree to be approached by someone from the research team for consent and possible inclusion in the study. This will be done in the anesthesia preoperative assessment clinic, or in the pre-op area on the day of surgery (if a patient was not seen in clinic).

Once consented, all patients in the study will have baseline measurements of their sensation and movement of the arm for surgery, as well as an ultrasound examination of the movement of the diaphragm.

Patients will then be randomized to either the single or double injection supraclavicular nerve block. The blocks will be performed by attending anesthesiologists with experience in regional anesthesia, or by residents and fellows under the direct supervision of such anesthesiologists.

Eligibility Criteria:
Inclusion Criteria:

* Patients presenting for unilateral upper extremity surgery below the level of the elbow (the forearm or hand) who are having a regional block for anesthesia
* Patient must be over 18 years old
* Weight greater than 50kg
* English speaking
* Be available to be contacted by phone on post-operative day 1
* ASA physical status 1-3
* BMI under 35 kg/m2

Exclusion Criteria:

* Inability to consent to study participation
* Pre-existing neuromuscular disease or severe neurological dysfunction
* Severe coagulopathy
* Severe obstructive or restrictive lung disease
* Pregnancy
* Prior surgery in the supraclavicular region
* Allergy to medications used in the study
* Known diaphragmatic dysfunction of either diaphragm
* Inability to visualize the diaphragm with ultrasound on the side of the surgical procedure
* Highly opioid-tolerant patient (\>40mg of morphine PO or equivalent per day for \>1month)
* Patient requests a general anesthesia technique
* Attending anesthesiologist preference for alternate anesthetic technique
* Surgeon or attending anesthesiologist request for a different anesthesia technique
* Current involvement in another study
A Quality of Life Study re Management of Malignant Pleural Effusions

There is much data in the literature regarding optimal treatment approaches for malignant pleural effusions as assessed by patient outcomes. However, data on quality of life and satisfaction with treatment from the patient's perspective is not available.

This study will compare various treatment strategies in the management of malignant pleural effusions with respect to:

1. Primary endpoint: the successful palliation of symptomatic pleural effusions as assessed by the London Chest Activity of Daily Living Scale (LCADLS)
2. Secondary endpoints:

   i) impact of treatment on patient quality of life as assessed by the Functional Assessment of Chronic Illness Therapy - Palliative patient (FACIT-PAL) questionnaire ii) Assessment of patient satisfaction with treatment received via Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction (FACIT-TS) questionnaire iii)Pleurodesis success rates assessed by 2 and 6-week effusion control rates on CXR iv) Requirement of further hospitalizations or procedures for the treatment of recurrent effusions v) Comparison of morbidity and mortality rates for differing treatment approaches vi) comparison of cost in a Canadian health care setting for differing treatment approaches

Eligibility Criteria:
Inclusion Criteria:

* symptomatic pleural effusion
* history of malignant disease
* age greater that 18 years
* consent to participate in study

Exclusion Criteria:

* significant ipsilateral endobronchial disease
* prior ipsilateral, intra-pleural therapy, as defined by: prior chest tube placement for effusion, prior attempt at chemical/surgical pleurodesis, prior surgical pleurectomy
* active pulmonary or pleural infection
* granulocytes \< 1500/mm3, platelets \< 50,000/mm3
* systemic chemotherapy within 2 weeks
* allergy to talc
EFficacy of Prophylactic Clip Application in Decrease of Immediate Postpolypectomy Bleeding and Delayed Postpolypectomy Bleeding After Colonoscopic Removal for a Large Pedunculated Polyps

The aim of this study is to evaluate the efficacy of prophylactic clip application after colonoscopic removal for a large pedunculated polyp (\> 1cm) in preventing immediate postpolypectomy bleeding (IPPB) and delayed postpolypectomy bleeding (DPPB).


Eligibility Criteria:
Inclusion Criteria:

* Patients who have a large pedunculated polyp(\>1cm) in the colon

Exclusion Criteria:

* Age under 20 years
* Subjects who are taking anticoagulants
* Subjects who have an abnormal coagulogram (platelet count, international normalized ratio, or activated partial thromboplastin time)
* Subjects who have inflammatory bowel diseases
The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease

Functional tricuspid regurgitation is common in patients with heart valve disease, replacement and repair both can correct this anomaly. However, there is no data to address which one can bring more benefits to these patients with combined heart valve disease. The investigators retrospectively review patients with two or more heart valve disease and functional tricuspid regurgitation, and assess its long term outcomes.

we reviewed patients who admitted to our hospital due to combined heart valve disease, and underwent tricuspid valve replacement or repair from January,1998 to december,2009. we made a comparison between these two groups, in term of early results after operation and long term results.

Eligibility Criteria:
Inclusion Criteria:

* Significant disorders in aortic and mitral valves
* Moderate ～ severe tricuspid regurgitation
* Underwent tricuspid repair or replacement operation

Exclusion Criteria:

* Isolate tricuspid valve lesion
* Mild tricuspid valve regurgitation
* Tricuspid valve regurgitation was left without surgical treatment
Registry for HF20 for Pediatric CRRT Under Emergency Use Authorization

Historically, innovations for acute kidney injury (AKI) and continuous renal replacement therapy (CRRT) have centered around an adult population. However, research has shown that over 10% of pediatric patients develop severe AKI within the first week in an intensive care unit (ICU). When a pediatric patient requires renal replacement therapy for AKI in the ICU, CRRT is usually the modality of choice. The HF20™ is indicated for supporting patients weighing 8 to 20 kilograms, addressing a critical clinical need for critically ill children who require CRRT. Current US Food and Drug Administration (FDA) approved CRRT filters are designed for patients weighing more than 20 kg or less than 10 kg, leaving a gap in appropriately designed filters for pediatric patients.

A previous trial in the US showed that the HF20™ is safe and effective, however the membrane composition of the HF20™ used in that trial is different than what is currently manufacturer and available. Baxter Healthcare Corporation has received an Emergency Use Authorization (EUA) for the currently available HF20™ to be used in the era of the COVID-19 pandemic, however participants do not need to be infected with the SAR-CoV-2 virus in order to be treated. The EUA for the HF20™ allows for treatment for any children weighing between 8 and 20 kilograms in need of CRRT. This registry will collect clinical data related to the safety and efficacy of the HF20™ filter for CRRT in pediatric patients weighing 8 to 20 kilograms at participating institutions, however participation in this registry is not a requirement in order to be treated with the HF20™ filter.


Eligibility Criteria:
Inclusion Criteria:

* Receiving or plan to receive CRRT with the HF20™ filter as standard of care
* Acute kidney injury (AKI) or fluid overload as defined as one of the two below:

  1. AKI defined as Kidney Disease Improving Global Outcomes (KDIGO) Stage 1 or higher by either:

     1. Serum creatinine criteria (0.3 mg/dL increase over baseline in 48 hours, or a 50 percent increase within the previous 7 days) or
     2. Urine output criteria (less than 0.5 mL/kg/hr for 6 or more hours)
  2. Severe fluid overload defined as greater than 10 percent fluid accumulation based on ICU admission weight

Exclusion Criteria:

* Weight less than 8 kilograms
* Weight more than 20 kilograms
* Patient not expected to survive more than 48 hours
* Received renal replacement therapy in the previous 5 days
Study of Nasal Mucosa Histopathological Changes in Chronic Hypersensitivity Pneumonitis

Background:Hypersensitivity pneumonitis (HP) is an interstitial lung disease that develops after inhalation of organic or inorganic antigens in susceptible individuals. The nasal mucosa is constantly exposed to these antigens that can irritate the respiratory mucosa.

Objectives: to assess the burden of sinonasal symptoms in HP patients and to evaluate the nasal histopathology in those patients.


Eligibility Criteria:
Inclusion Criteria:

* all patients with clinical and radiological features of HP

Exclusion Criteria:

* respiratory failure
* patients on anticoagulants
Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects

The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.

This study will address the respective and combined impact of (i) timing between blood collection and peripheral blood mononuclear cells (PBMC) processing \["time-to-process"\] and (ii) timing of PBMC resting before stimulation \["resting -time"\].

Eligibility Criteria:
Inclusion Criteria:

All subjects must satisfy all the following criteria at study entry:

* Subjects who the Investigator believes can and will comply with the requirements of the protocol.
* Written informed consent obtained from the subject prior to any study procedure.
* A male or female between and including 18 and 55 years of age at the time of enrollment.
* Confirmed HIV-1 infection.
* ART-naïve and not eligible for ART treatment as per established guidelines. Subjects must never have received ART after HIV diagnosis, including lamivudine used for chronic hepatitis B infection. The exception to this is short-term ART for prevention of mother-to-child transmission (PMTCT) which must have been completed at least 360 days prior to enrollment.
* Viral load level between and including 2,000 and 100,000 copies/mL at screening.
* CD4+ T cell count \>500 cells/mm3 at screening.
* If the subject is female, she must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal. Female subjects of childbearing potential may be enrolled in the study, if the subject:

  * has practiced adequate contraception for 30 days prior to vaccination, and
  * has a negative pregnancy test at screening, and
  * has agreed to continue adequate contraception during the entire study period.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If any exclusion criterion applies, the subject must not be included in the study:

* Infection with HIV-2. This includes subjects with dual infection with HIV-1/HIV-2.
* Planned use of any hematotoxic product during the study period.
* Planned use of any investigational or non-registered product during the study period.
* Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, serology and/or medical history at screening.
* Grade 3 or grade 4 laboratory abnormalities, as defined by Division of AIDS (DAIDS) grading table, at screening.
* Any condition which, in the opinion of the Investigator, could compromise the subject's adherence to the study protocol.
* Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the Sample Collection Visit (Visit 2). Vaccine can be administered as after sampling in Visit 2.
* Pregnant or lactating female.
Adolescent Attention to Emotion Study

Rates of depression increase rapidly during adolescence, especially for girls, and, thus, research is needed to spur the development of novel interventions to prevent adolescent depression. This project seeks to determine if a novel visuocortical probe of affect-biased attention (i.e., steady-state visual evoked potentials derived from EEG) can 1) be used to prospectively predict depression using a multi-wave repeated measures design and 2) modify affect-biased attention and buffer subsequent mood reactivity using real time neurofeedback. This work could ultimately lead to improved identification of adolescents who are at high risk for depression and directly inform the development of mechanistic treatment targets to be used in personalized intervention prescriptions for high-risk youth.


Eligibility Criteria:
Inclusion Criteria:

* Participants will include 90 female adolescents ages 13 years 0 months through 15 years 11 months at study entry.

Exclusion Criteria:

1. Lifetime history of any DSM 5 depressive disorder
2. Lifetime history of taking antidepressants (e.g., SSRIs)
3. Lifetime history of a DSM 5 psychotic, bipolar, or autistic spectrum disorder.
4. Presence of EEG contraindications (e.g., personal lifetime history of seizures or family history of hereditary epilepsy).
5. Being pre-pubertal
6. Lifetime history of a neurological or serious medical condition.
7. Lifetime history of head injury or congenital neurological anomalies (based on parent report).
8. IQ less than 80, as assessed using the Wechsler Abbreviated Scale of Intelligence (WASI).
9. Uncorrected visual disturbance
10. Being acutely suicidal or at risk for harm to self or others.
Post Marketing Clinical Evaluation Assessing the Visual Performance of Hanita Lenses "Intensity SL" Intraocular Lens

This clinical study will assess the safety and performance of Intensity SL IOL, 1 year post operation.

The study will also evaluate the patient satisfaction of the implanted patients.

Study Design:

This study is an ambispective, single arm single center, open label study.

Study Objectives:

The aim of this study is to evaluate performance of Hanita Lenses Intensity SL IOL. The primary aim of this study is to evaluate the binocular defocus Curve and visual acuity for far, intermediate and near distance after Intensity SL IOL implantation.

The second aim of this study is to evaluate the patient satisfaction 12 to 24 months post-operation.

Study population:

Men and women who had implantation on both eyes using Hanita Lenses SeeLens SL IOL, for 12 to 24 months post operation.

Enrollment:

The study will encompass a total of 60 eligible subjects implanted bilaterally (120 eyes) in total who will complete the protocol follow-up schedule.

Duration of Subject participation:

Duration of Subject participation is at most one month Completion of active enrolment is anticipated to last approximately 6 months. The primary aim will be finally evaluated when the last study subject has been recruited.

Visits \& Procedures Patients participating in the trial will attend a total of one visit (1 year follow up visit).

Subjects will be selected from the physician's usual subjects' practice. All subjects meeting the inclusion criteria and having signed the Informed Consent Form will be evaluated by the Investigator according to the study protocol.

1 year follow up visit: Pre-operation Visit: performed to check inclusion criteria, and to sign the informed consent.

Eligibility Criteria:
Inclusion Criteria:

* Implanted bilaterally using Hanita Intensity SL IOL
* 12 to 24 months post implantation
* Signed informed consent

Exclusion Criteria:

• Patients with any other pre-implantation and post implantation eye disease or condition that might affect the safety and efficacy evaluation.
Pain Management in Outpatient Urologic Procedures

Goal of this study is to evaluate how pain is controlled after outpatient urologic surgeries. Patients will receive either opioid pain medication or non-opioid medication for pain control. A survey will be conducted at the post-operative appointment to evaluate for pain control.

Patients will be approached in the pre-operative area prior to their outpatient urologic surgery. Informed Consent will be obtained at that time. Patients will be instructed that they will receive a prescription for either opioid pain medication or non-opioid medication for after surgery. The opioid medication includes oxycodone, while the non-opioid includes ketoralac, a non-steroidal anti-inflammatory medication. Subjects will be assigned randomly to either medication. Standard of care after outpatient urologic surgery is either oxycodone or ketoralac, however there is no previous research on whether one is superior than the other. These drugs were chosen because they are the most commonly used medications after outpatient urologic surgery. The study team and patients will not be blinded to the treatment.

They will also receive instructions for non-opioid pain management. If the patients require additional pain medication after surgery, they are instructed to call the provider's office for further evaluation and treatment. The patient's physician will prescribe further medication if warranted. The post-operative appointment is scheduled 2-3 weeks after surgery. At the post-operative appointment, patients will then be given a four question paper survey inquiring how well their pain was managed, how many pills were taken, if any additional non-opioid medications were taken for pain, and how the extra pills were disposed. Other PHI that will be collected includes patient's age, gender, past medical history, past surgical history, renal function, prior medications, and current surgery.

Eligibility Criteria:
Inclusion Criteria:

* outpatient urologic surgery
* age 18 and over

Exclusion Criteria:

* renal dysfunction
* non-English speaking
* employees of organization
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients

A critical aspect of real-world functioning following kidney transplantation involves how adherent individuals are to their medication regimens. Regardless of the possible dangers of failing to adhere to anti-rejection medications, such as increased graft rejection, studies have reported rates of non-adherence at almost 50% following renal transplant.

The Cognitive Aging Laboratory under the direction of Dr. Wendy Thornton, at Simon Fraser University, has previously identified relationships between several potentially important cognitive and psychosocial variables, and self-reported medication adherence in renal transplant recipients, including depressive symptoms, as well as everyday and traditional cognitive functioning \[4\]. The possibility that changes in dosing regimens for a given medication may have an additional impact on medication adherence presents an important issue worth further exploration.

The current study will allow for more thorough delineation of the roles of psychosocial and cognitive predictors of adherence with state-of-the-art monitoring techniques. In addition, the investigators will assess whether different dosing formulations of tacrolimus impact adherence behaviors in renal transplant recipients.

The proposed research has two primary aims to examine:

1. To examine the role of cognitive and psychosocial variables in predicting medication adherence in renal transplant recipients.
2. To examine whether different formulations of tacrolimus (once per day dosing versus twice per day dosing) will impact medication adherence in renal transplant recipients.


Eligibility Criteria:
Inclusion Criteria:

* a minimum of one year post renal transplant with a successful kidney graft and stable renal function (estimated glomerular filtration rate \[GFR (glomerular filtration rate)\] above 25 ml/minute per 1.73 m2).
* currently prescribed tacrolimus
* able to swallow pills
* a minimum of grade six education
* fluent in the English language.

Exclusion Criteria:

* refusal to or inability to give written informed consent.
* any visual, hearing or other sensory/motor impairments which may interfere with the testing procedures.
* have had a stroke determined to be of significant severity
* have had a head injury determined to be of significant severity
* have a current psychiatric diagnosis determined to be of significant severity
* have the presence of an acute illness (e.g., metastatic cancer), neurological disease, and other major organ failure (e.g., end stage liver disease)